Ruvim Izĭckson on a joint flu and COVID-19 vaccine

from The Lancet Respiratory Medicine in conversation with · host The Lancet Respiratory Medicine

Ruvim Izĭckson discusses the safety and immunogenicity of administering a high-dose quadrivalent influenza vaccine together with a third dose of the Moderna COVID-19 vaccine in adults aged 65 years and older. Read the full article: Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 year Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Episode metadata supplied by the publisher feed · Published Jan 31, 2022

Embed this episode

Attribution link and audio player

NOW PLAYING

Ruvim Izĭckson on a joint flu and COVID-19 vaccine

0:00 8:41

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Lancet Respiratory Medicine in conversation with?

This episode is 8 minutes long.

When was this The Lancet Respiratory Medicine in conversation with episode published?

This episode was published on January 31, 2022.

Can I download this The Lancet Respiratory Medicine in conversation with episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!